Partial
Partially Aligned
Patient Risk:
Medium
Summary
Many basic product/ingredient and acute-migraine indication statements align with the label, but several safety-related claims are overstated or not supported by the provided label text (notably generic/availability and some risk framing). Key dosing details (strength-specific pediatric/adult dosing, max daily limits) are omitted, and some warnings are only partially captured.
Category Scores
Accurate Statements
Treximet is a prescription medicine that combines sumatriptan and naproxen.
Drug name/active ingredients provided; label indicates fixed-dose combination of sumatriptan and naproxen sodium (Drug/Active ingredients).
Treximet is used to treat acute migraine attacks in adults.
Section 1: indicated for acute treatment of migraine in adults.
Treximet is indicated for treatment of acute migraine attacks.
Section 1: indicated for acute treatment of migraine with or without aura.
Treximet contains an NSAID (naproxen) and a triptan (sumatriptan).
Active ingredients are sumatriptan succinate (triptan class) and naproxen sodium (NSAID) as reflected by “sumatriptan and naproxen sodium” and warnings sections referencing both.
Sumatriptan in Treximet helps relieve migraine by acting on serotonin (5-HT1B/1D) receptors.
Not explicitly provided in the excerpted label text you supplied; cannot confirm from provided sections.
Naproxen in Treximet is a nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain and inflammation.
Naproxen is an NSAID referenced in warnings/sections as “NSAIDs, including naproxen…”. The specific “reduce pain and inflammation” wording is not present in the provided excerpts.
Treximet pairs a migraine-specific medicine (sumatriptan) with an NSAID (naproxen) in one product.
Drug/Active ingredients: fixed-dose combination of sumatriptan and naproxen sodium.
Treximet is a sumatriptan/naproxen combination product.
Drug/Active ingredients and name: sumatriptan and naproxen sodium combination.
Treximet can be unsafe for some people, including those with certain cardiovascular conditions or risk factors.
Contraindications and warnings include ischemic/vasospastic CAD and CABG setting; also risk of cardiovascular thrombotic events.
Treximet can be unsafe for some people, including those with NSAID-related contraindications.
Contraindications include history of aspirin/NSAID-related hypersensitivity; boxed-style/Warnings include serious GI and CV risks from NSAID component.
Treximet has medication-interaction and kidney/GI risk considerations typical of NSAIDs and triptans.
Provided label excerpts include drug interaction warnings (e.g., anticoagulants/antiplatelets/SSRIs/SNRIs, aspirin) and renal toxicity/GI bleeding warnings.
Unsupported Statements
Treximet is taken when migraine symptoms begin (early in the attack).
The provided label excerpts include indication as acute treatment and do not provide administration timing language (e.g., “when symptoms begin”).
Sumatriptan in Treximet helps relieve migraine by acting on serotonin (5-HT1B/1D) receptors.
The provided label excerpts do not include mechanism text referencing 5-HT1B/1D receptors.
Naproxen in Treximet is a nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain and inflammation.
While naproxen is referenced as an NSAID in warnings, the specific “helps reduce pain and inflammation” mechanism/effect wording is not present in the supplied excerpts.
Treximet may be used by people who need both sumatriptan and NSAID effects for migraine relief rather than separate dosing.
The label excerpts provided do not discuss rationale for choosing combination vs separate agents.
Common side effects of Treximet can include nausea and other GI-related effects.
The provided excerpts do not list adverse reactions/side effects (Section 6 adverse reactions are not populated with specific common side effects).
Common side effects of Treximet can include sensations such as dizziness or flushing.
The provided excerpts do not list adverse reactions/side effects (no dizziness/flushing data shown).
Treximet has more serious risks for NSAIDs and triptans that depend on personal health history.
The label clearly includes contraindications/risks, but this generalized “depend on personal health history” phrasing is not stated as such in the supplied excerpts.
Other combination strategies exist for migraine, but Treximet specifically pairs sumatriptan with naproxen.
The label excerpts provided do not discuss other combination strategies for migraine; only Treximet’s combination is supported.
Treximet generic availability can change over time based on patent status and approvals.
The provided label excerpts do not address generic availability or patent/approval status.
Contradictions
Important Omissions
Approved population breadth and limitations: pediatric patients 12+ (not only adults), and that TREXIMET is not indicated for prevention; also limitation to use only after clear migraine diagnosis and reconsider diagnosis if no response to first treated attack.
Importance:
Moderate
Dosage and administration specifics: adult recommended dose (85/500 mg), max 2 tablets per 24 hours at least 2 hours apart, pediatric 12–17 dosing (10/60 mg) max 1 tablet per 24 hours, and safety limits on number of attacks per 30 days not established.
Importance:
High
Contraindication details beyond broad “cardiovascular conditions” or “NSAID contraindications,” including explicit contraindications: ischemic CAD/vasospastic CAD including Prinzmetal’s, CABG setting, history of stroke/TIA/hemiplegic/basilar migraine, aspirin/NSAID-related asthma/urticaria/allergic-type reactions, hypersensitivity to sumatriptan/naproxen/components, and severe hepatic impairment.
Importance:
High
Key warnings/monitoring elements: GI bleeding/ulceration/perforation (can occur without warning), CV thrombotic events with specific risk minimization guidance, hypertension monitoring, renal toxicity management/discontinuation, and discontinuation with arrhythmias or cerebrovascular events; also mention of anaphylaxis/serious skin reactions.
Importance:
Moderate
Specific drug-interaction monitoring: anticoagulants/antiplatelets and SSRIs/SNRIs bleeding monitoring; aspirin coadministration increases GI adverse reactions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Safety-related content is partially present (general contraindication/risk and GI/CV/renal considerations), but several unsupported generalizations and missing key contraindication details and dosing limits reduce label fidelity. The absence of precise contraindication/dosing and adverse reaction specifics could mislead about safe use boundaries.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided label excerpts (mechanism details, timing of dosing during attack, specific common side effects, generic availability), and important label elements (exact contraindications, dosing limits, pediatric scope, and key warnings/monitoring) are omitted.
Suggested Improvement
Restrict statements to label-supported excerpts (acute treatment indication and combination components), add label-accurate dosing and contraindication/warning specifics (including max daily limits and explicit contraindications), and remove or qualify unsupported claims (5-HT1B/1D mechanism wording, early-in-attack timing, common side effect examples, and generic availability).